Toggle navigation
Home
Search
Services
Blog
Contact
About
Post Exposure Prophylaxis Against HIV 1 by CD4 IGG2
Maddon, Paul J.
Progenics Pharmaceuticals, Inc., Tarrytown, NY, United States
Search 24 grants from Paul Maddon
Search grants from Progenics Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Vascular Pain Mechanisms
Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance
The Role of Hedgehog Interacting Protein in Sonic Hedgehog Mediated Agiogenesis
Lung Cancer and Diesel Exhaust Exposure
Skeletal Muscle Augmentation of Ventricular Volume
Recently added grants:
Protein carbamylation and uremic cardiomyopathy in chronic kidney disease
Purinergic Regulation of Veinous Endothelial Permeability
Molecular regulation of ventricular chamber maturation
Identification of immune cell-cell communication networks and inflammatory pulmonary microenvironments associated with the progression of COPD
Unconventional IL-1 signaling in heart failure
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI036818-02
Application #
2004162
Study Section
Special Emphasis Panel (ZRG5-ARRA (01))
Project Start
1996-09-30
Project End
1998-09-29
Budget Start
1996-09-30
Budget End
1997-09-29
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Progenics Pharmaceuticals, Inc.
Department
Type
DUNS #
945494490
City
Tarrytown
State
NY
Country
United States
Zip Code
10591
Related projects
NIH 1997
R44 AI
Post Exposure Prophylaxis Against HIV 1 by CD4 IGG2
Maddon, Paul J. / Progenics Pharmaceuticals, Inc.
NIH 1996
R44 AI
Post Exposure Prophylaxis Against HIV 1 by CD4 IGG2
Maddon, Paul J. / Progenics Pharmaceuticals, Inc.
Comments
Be the first to comment on Paul Maddon's grant